

THURSDAY, OCTOBER 13, 2011

TOPIC: The Importance of Cellular Therapies in Treating Serious Medical Diseases

SPEAKER: Neil Warma, President & CEO, Opexa Therapeutics, Inc.

Industry experts agree that cell therapy, which has been shown to have applications in a large number of disorders, is bound to become a part of medical practice. Cell therapy technologies and methods have already started to play an important role in the practice of medicine and to have an impact on biopharma companies. As of 2005, the value of the collective cell therapy market was approximately \$26.6 billion. This figure is expected to increase to \$96.3 billion by 2015, according to an industry report.

At this program, Mr. Neil Warma, an expert in cell therapy and a frequent speaker at cell therapy conferences worldwide, will explain how biopharma companies can take advantage of cell therapy to increase business opportunities. His discussion will include:

- A general overview and description of cellular therapies
- Progress in the field worldwide
- Diseases that have the potential to be treated with cellular therapies
- How T-cell therapy can be tailored to match an individual patient's disease profile and how that may lead to significantly improved benefit/risk profile
- Description of the manufacturing process, scaling for commercialization and the importance of automation

Mr. Warma has more than 20 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, a publicly-traded company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. Mr. Warma served as President & CEO and a member of the Board of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company developing a novel class of protein therapeutics. Before Viron, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies. MedExact was ultimately sold to a large public European firm. Prior to MedExact, he held several senior management positions in international policy and advocacy and global marketing at the corporate headquarters of Novartis Pharmaceuticals in Basel, Switzerland.